United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer's transition from COVID revenue faces skepticism, as PFE underperformed its healthcare peers recently. Successful integration of Seagen is crucial for Pfizer's oncology portfolio, potentially lifting investor sentiment. Pfizer's cautious approach to weight loss drugs suggests success is far from certain, raising its execution risks to disrupt the market.

Pfizer: Undervalued Healthcare Leader Poised For Further Recovery

Pfizer Inc. (PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and antiviral therapy, establishing a household name in the process. As the pandemic faded, the stock lost over 50% of its value from its all-time high.

Pfizer Is Rising Past Covid-19

Moderna

Pfizer and Moderna have seen their shares drop as their coronavirus-related tailwind ended. Yet, both companies have exciting pipelines and have earned important approvals recently.

2 Beaten-Down Stocks to Buy and Hold for a Decade

CRISPR Therapeutics

Gilead Sciences

CRISPR Therapeutics is still in its early stages of growth. Gilead Sciences remains an underrated stock.

3 Dirt Cheap Stocks to Buy Right Now

In the closing of the recent trading day, Pfizer (PFE) stood at $29.42, denoting a -0.83% change from the preceding trading day.

Here's Why Pfizer (PFE) Fell More Than Broader Market

CVS Health

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

BioNTech SE

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies' Omicron KP.2-adapted monovalent COVID-19 vaccine (COMIRNATY® KP.2) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The European Commission wil.

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.

Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?

Baxter

Bristol-Myers

Humana

Healthcare is undervalued despite being the top sector for earnings growth, making it an attractive investment with solid fundamentals and the potential for explosive returns in 2025. Investing in healthcare ETFs or individual undervalued healthcare stocks can capitalize on the sector's recovery and expected double-digit growth through 2026. Screening for blue-chip healthcare stocks with solid fundamentals and fair valuations can yield superior returns, including these five coiled spring blue chips.

5 Incredible Healthcare High-Yield Blue-Chip Bargain Buys For 2025

Verizon

W. P. Carey

Now that W.P. Carey is no longer in the office-leasing business, its long-term investors can rest much easier.

3 Magnificent Dividend Stocks With Yields Above 5% to Buy Now and Hold Forever

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, October 29, 2024. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Third Quarter 2024 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. I.

Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts

The healthcare giant was a star stock during the height of the pandemic thanks to its vaccine. Some Pfizer investors are hungry for an encore and showing their displeasure by shunning the stock.

Is Pfizer Stock Going to $36? 1 Wall Street Analyst Thinks So.

Unum

Three large-cap stocks ??? AES, PFE and UNM?

Buy 3 High Dividend-Paying Stocks With Attractive Short-Term Returns

Pfizer (PFE) said this weekend that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial.

Pfizer Drug Treating Fatal Weight Loss in Cancer Patients Found Effective

Newpark Resources

MEUDON, France--(BUSINESS WIRE)-- #ThalesIDWallet--On September 16th, Thales celebrates the International Identity Day (ID Day), a symbolic day to highlight the United Nations' Sustainable Development Goal 16.9 to provide a legal identity for all. ID Day is dedicated to raising awareness about the importance of legal identity as a fundamental human right and a key enabler of inclusive social and economic development. Thales supports global efforts to guarantee every individual has access to a secure and trusted.

International ID Day: Thales Stands up for a Legal and Trusted Identity for Everyone

Pfizer's 5.7% dividend yield stands out in the healthcare sector. The company's 436% payout ratio raises concerns about dividend sustainability.

Is Pfizer's 5.7% Dividend Yield Worth the Risk?

Pfizer said its experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial. Patients with the condition, called cancer cachexia, who took Pfizer's treatment saw improvements in body weight, muscle mass, quality of life and physical function.

Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia and elevated levels of GDF-15. Cachexia is a common, life-threatening wasting condition that can significantly impact quality of life in affected patients with cancer.ii,iii Results will be presented t.

Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates could grow to become the standard of care.

Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC). After an additional 18 months of follow-up, the objective response rate (ORR) and the median duration of response (DoR) as assessed by independent radiology review.

Pfizer's BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Barrett Business Services

Peabody Energy

G-III Apparel Group

Hamilton Insurance Group Ltd

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like GIII, BTU, HG, BBSI and PFE hold promise.

5 Bargain Price-to-Sales Stocks With High Growth Prospects

Baidu

Cisco Systems

Finding stocks that trade at discounts can set investors up for significant gains in the long run. The stocks listed here are facing headwinds right now, but their growth prospects remain promising.

Got $5,000? 3 Dirt Cheap Stocks to Buy Right Now

Moderna may have a number of new product launches ahead. Pfizer is a big pharma stock that's poised for a big comeback.

A Bull Market Is Here: 2 High-Potential Stocks Down More Than 50% to Buy Right Now

AbbVie

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward, versus 20x for ABBV, and we think this gap in valuation will narrow in favor of Pfizer in the coming years.

Pfizer Stock Vs. AbbVie

Eli Lilly

Novartis

Roche Holding AG

Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.

News for Pfizer Stock (PFE)